Indian Journal of Dermatology
  Publication of IADVL, WB
  Official organ of AADV
Indexed with Science Citation Index (E) , Web of Science and PubMed
Users online: 7901  
Home About  Editorial Board  Current Issue Archives Online Early Coming Soon Guidelines Subscriptions  e-Alerts    Login  
    Small font sizeDefault font sizeIncrease font size Print this page Email this page
Year : 2009  |  Volume : 54  |  Issue : 4  |  Page : 350-356

Efficacy and tolerability of cefditoren pivoxil in uncomplicated skin and skin structure infections in Indian patients

1 Medical Affairs and Clinical Research, Ranbaxy Laboratories Ltd, 77-B, IFFCO Road, Sector-18, Udyog Vihar Industrial Area, Gurgaon, Haryana, India
2 Department of Dermatology, Kamineni Institute of Medical Sciences, Naketpally, Nalgonda, India
3 Princess Esra Hospital, Hyderabad, India
4 Department of Dermatology, Stanley Govt Hospital, Chennai, India
5 Anand Bazar Main Road, Indore, India
6 Department of Dermatology, PSG Hospitals, Coimbatore, India
7 BYL Nair Charitable Hospital & TNMC, Mumbai, India
8 Department of Surgery, Govt. Medical College & Shri Sayajirao General Hospital, Vadodara, India
9 Department of Dermatology and STD, GMC and New Civil Hospital, Surat, India
10 Flora Apartments, Besides Almond House, Road No. 3, Banjara Hills, Hyderabad, India
11 Hari Clinic, 3/95, Kamal Kunj, Vikas Nagar, Lucknow, India
12 Raghu Skin Clinic, Suvarna Complex, Karver Road, Kothrud, Pune, India
13 Department of Dermatology, Govt. Medical College, Nagpur, India
14 Foundation for Medical Research, Near Flora Dinning Restaurant, Worli Sea Face, Mumbai, India
15 Department of Skin & STD, Victoria Hospital, Bangalore Medical College, Bangalore, India
16 Skin & VD, Shangrila Garden, Bund Garden Corner, Pune, India
17 Dr. Shaukat's Nursing Home, Natawala Building, Cadell Road, Mahim (W), Mumbai, India
18 Department. of Skin & VD, Medical College & SSG Hospital, Vadodara, India

Correspondence Address:
Charu Manaktala
Medical Affairs and Clinical Research, Ranbaxy Research Laboratories, 77B, IFFCO Road, Sector 18, Udyog Vihar Industrial Area, Gurgaon, Haryana - 122 015
Login to access the Email id

Source of Support: Ranbaxy Laboratories Ltd, India., Conflict of Interest: Cefdinir used in the study is manufactured by Ranbaxy Laboratories Ltd, one of the authors (CM) is full time employee of Ranbaxy Laboratories Ltd.

DOI: 10.4103/0019-5154.57612

Rights and Permissions

Background: Uncomplicated skin and skin structure infections (uSSSI) are commonly encountered community-acquired infections and are typically confined to the superficial layers of the skin. Hence, they seldom lead to the destruction of skin structures. Aims: To evaluate the efficacy and tolerability of cefditoren pivoxil in uSSSI in Indian patients. Methods: One hundred and seventy-eight patients diagnosed with uncomplicated SSSI were enrolled in this randomized, comparative, multicentric study. Patients received either cefditoren pivoxil or cefdinir for ten days. Efficacy was assessed both clinically and microbiologically. Safety evaluation consisted of reporting of type, frequency, severity, and causal relationship of adverse events. Results: One hundred and fifty-one patients completed the study. Clinical and bacteriological efficacy of cefditoren pivoxil was comparable to that of cefdinir in the treatment of uSSSI. One hundred and five patients were eligible for per protocol (PP) analysis of bacteriological outcome and clinical efficacy. Clinical cure or improvement was achieved in 98.00% patients treated with cefditoren pivoxil and 98.18% patients treated with cefdinir. In the modified Intent to Treat (mITT) patient population, clinical cure or improvement was recorded in 97.33% patients treated with cefditoren pivoxil and 96.20% patients treated with cefdinir. Microbiological eradication (or presumed eradication) was recorded in 88.00% patients treated with cefditoren pivoxil and 94.55% patients treated with cefdinir. The above differences in the outcome rates between the two drugs were not statistically significant. Six adverse events (AEs) (two in cefditoren group and four in cefdinir group) were reported in this study. Conclusion: Cefditoren pivoxil 200 mg b.i.d. was effective and well tolerated in the treatment of uSSSI.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded194    
    Comments [Add]    
    Cited by others 1    

Recommend this journal